<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4554">
  <stage>Registered</stage>
  <submitdate>10/12/2013</submitdate>
  <approvaldate>10/12/2013</approvaldate>
  <nctid>NCT02010775</nctid>
  <trial_identification>
    <studytitle>Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>191622-130</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Masticatory Muscles, Hypertrophy of</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - botulinum toxin Type A
Treatment: drugs - Normal saline

Active Comparator: BOTOX® 24U - Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Active Comparator: BOTOX® 48U - Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Active Comparator: BOTOX® 72U - Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Active Comparator: BOTOX® 96U - Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Placebo Comparator: Placebo - Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.


Other interventions: botulinum toxin Type A
Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Treatment: drugs: Normal saline
Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Lower Facial Volume Calculated by Digital Imaging</outcome>
      <timepoint>Day 90</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Investigator's Assessment of Masseter Muscle Hypertrophy (MMH) using a 5-Point Scale</outcome>
      <timepoint>Baseline, Day 90</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participants with Masseter Muscle Hypertrophy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis,
             or any other condition that might interfere with neuromuscular function

          -  Prior botulinum toxin treatment of any serotype to the masseter muscle or lower face

          -  History of dental or surgical procedure for lower facial shaping or masseter muscle
             reduction

          -  History of or current temporomandibular joint disorder (TMJD) or Class III
             malocclusion.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>20/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>188</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>13/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,WA</recruitmentstate>
    <hospital>Shape Clinic - Darlinghurst</hospital>
    <hospital>Central Sydney Dermatology - Sydney</hospital>
    <hospital>Esteem Medi Spa - Main Beach</hospital>
    <hospital>The Rose Medical &amp; Aesthetic Centre - North Fremantle</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2000 - Sydney</postcode>
    <postcode>4217 - Main Beach</postcode>
    <postcode>6159 - North Fremantle</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Taiwan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type
      A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02010775</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jasmina Jankicevic</name>
      <address>Allergan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>